{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:32:05Z","timestamp":1791775925649,"version":"4.3.4"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["AIRC5x1000 22737"],"award-info":[{"award-number":["AIRC5x1000 22737"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["AIRC-IG 18458"],"award-info":[{"award-number":["AIRC-IG 18458"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["ID 29914 - 2023"],"award-info":[{"award-number":["ID 29914 - 2023"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-67263-w","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:35:04Z","timestamp":1767875704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0038-6233","authenticated-orcid":false,"given":"Martina","family":"Spiga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0298-7315","authenticated-orcid":false,"given":"Alessia","family":"Potenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulma","family":"Magnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Beretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Camisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Airaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8616-3377","authenticated-orcid":false,"given":"Laura","family":"Perani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4969-5216","authenticated-orcid":false,"given":"Claudio","family":"Doglioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0055-325X","authenticated-orcid":false,"given":"Maurilio","family":"Ponzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4046-8420","authenticated-orcid":false,"given":"Francesca","family":"Sanvito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7362-3530","authenticated-orcid":false,"given":"Chiara","family":"Balestrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Sergi Sergi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2568-9815","authenticated-orcid":false,"given":"Oronza A.","family":"Botrugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2973-5038","authenticated-orcid":false,"given":"Giovanni","family":"Tonon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8517-7937","authenticated-orcid":false,"given":"Danilo","family":"Abbati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Iozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8611-5639","authenticated-orcid":false,"given":"Maximilian","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Algul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Pocaterra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5934-9273","authenticated-orcid":false,"given":"Martina","family":"Fiumara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1122-1231","authenticated-orcid":false,"given":"Samuele","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Ugolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Grometto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Di Lullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1024-9128","authenticated-orcid":false,"given":"Giovanni","family":"Sitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Belfiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Protti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0460-3426","authenticated-orcid":false,"given":"Renato","family":"Ostuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mondino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Reni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9654-7243","authenticated-orcid":false,"given":"Massimo","family":"Falconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7835-527X","authenticated-orcid":false,"given":"Luigi","family":"Naldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2954-8278","authenticated-orcid":false,"given":"Eliana","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0772-1674","authenticated-orcid":false,"given":"Chiara","family":"Bonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"67263_CR1","doi-asserted-by":"publisher","unstructured":"Uslu, U. & June, C. H. Beyond the blood: Expanding CAR T cell therapy to solid tumors. Nat. Biotechnol. 1\u201310 https:\/\/doi.org\/10.1038\/s41587-024-02446-2 (2024).","DOI":"10.1038\/s41587-024-02446-2"},{"key":"67263_CR2","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abm2077","volume":"7","author":"A Purcarea","year":"2022","unstructured":"Purcarea, A. et al. Signatures of recent activation identify a circulating T cell compartment containing tumor-specific antigen receptors with high avidity. Sci. Immunol. 7, eabm2077 (2022).","journal-title":"Sci. Immunol."},{"key":"67263_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38946-z","volume":"14","author":"J Schmidt","year":"2023","unstructured":"Schmidt, J. et al. Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors. Nat. Commun. 14, 3188 (2023).","journal-title":"Nat. Commun."},{"key":"67263_CR4","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M. & Maitra, A. Pancreatic cancer: Advances and challenges. Cell 186, 1729\u20131754 (2023).","journal-title":"Cell"},{"key":"67263_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"Cancer J. Clin."},{"key":"67263_CR6","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.3389\/fimmu.2018.01878","volume":"9","author":"D Kabacaoglu","year":"2018","unstructured":"Kabacaoglu, D., Ciecielski, K. J., Ruess, D. A. & Alg\u00fcl, H. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: Current limitations and future options. Front. Immunol. 9, 1878 (2018).","journal-title":"Front. Immunol."},{"key":"67263_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"67263_CR8","doi-asserted-by":"publisher","unstructured":"Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature https:\/\/doi.org\/10.1038\/s41586-024-08508-4 (2025).","DOI":"10.1038\/s41586-024-08508-4"},{"key":"67263_CR9","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s43018-020-00121-4","volume":"1","author":"NG Steele","year":"2020","unstructured":"Steele, N. G. et al. Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer. Nat. Cancer 1, 1097\u20131112 (2020).","journal-title":"Nat. Cancer"},{"key":"67263_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55424-2","volume":"16","author":"S Sivakumar","year":"2025","unstructured":"Sivakumar, S. et al. Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms. Nat. Commun. 16, 1397 (2025).","journal-title":"Nat. Commun."},{"key":"67263_CR11","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nm.2700","volume":"18","author":"E Provasi","year":"2012","unstructured":"Provasi, E. et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18, 807\u2013815 (2012).","journal-title":"Nat. Med."},{"key":"67263_CR12","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1182\/blood-2016-08-732636","volume":"130","author":"S Mastaglio","year":"2017","unstructured":"Mastaglio, S. et al. NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease. Blood 130, 606\u2013618 (2017).","journal-title":"Blood"},{"key":"67263_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg8027","volume":"14","author":"E Ruggiero","year":"2022","unstructured":"Ruggiero, E. et al. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. Sci. Transl. Med. 14, eabg8027 (2022).","journal-title":"Sci. Transl. Med."},{"key":"67263_CR14","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1136\/gutjnl-2022-328042","volume":"72","author":"A Potenza","year":"2023","unstructured":"Potenza, A. et al. Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells. Gut 72, 1887\u20131903 (2023).","journal-title":"Gut"},{"key":"67263_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40755-3","volume":"14","author":"JD Worboys","year":"2023","unstructured":"Worboys, J. D. et al. TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation. Nat. Commun. 14, 5016 (2023).","journal-title":"Nat. Commun."},{"key":"67263_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","volume":"38","author":"NA Manieri","year":"2017","unstructured":"Manieri, N. A., Chiang, E. Y. & Grogan, J. L. TIGIT: A key inhibitor of the cancer immunity cycle. Trends Immunol. 38, 20\u201328 (2017).","journal-title":"Trends Immunol."},{"key":"67263_CR17","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston, R. J. et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 26, 923\u2013937 (2014).","journal-title":"Cancer Cell"},{"key":"67263_CR18","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41588-022-01157-1","volume":"54","author":"D Cui Zhou","year":"2022","unstructured":"Cui Zhou, D. et al. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer. Nat. Genet 54, 1390\u20131405 (2022).","journal-title":"Nat. Genet"},{"key":"67263_CR19","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.ccell.2021.07.007","volume":"39","author":"WA Freed-Pastor","year":"2021","unstructured":"Freed-Pastor, W. A. et al. The CD155\/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell 39, 1342\u20131360.e14 (2021).","journal-title":"Cancer Cell"},{"key":"67263_CR20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1053\/j.gastro.2023.05.036","volume":"165","author":"S Yousuf","year":"2023","unstructured":"Yousuf, S. et al. Spatially resolved multi-omics single-cell analyses inform mechanisms of immune dysfunction in pancreatic cancer. Gastroenterology 165, 891\u2013908.e14 (2023).","journal-title":"Gastroenterology"},{"key":"67263_CR21","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1158\/1078-0432.CCR-23-0258","volume":"29","author":"M Heiduk","year":"2023","unstructured":"Heiduk, M. et al. TIGIT expression delineates T-cell populations with distinct functional and prognostic impact in pancreatic cancer. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 29, 2638\u20132650 (2023).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"67263_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36296-4","volume":"14","author":"G Werba","year":"2023","unstructured":"Werba, G. et al. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Nat. Commun. 14, 797 (2023).","journal-title":"Nat. Commun."},{"key":"67263_CR23","doi-asserted-by":"publisher","first-page":"101184","DOI":"10.1016\/j.esmoop.2023.101184","volume":"8","author":"A Rousseau","year":"2023","unstructured":"Rousseau, A., Parisi, C. & Barlesi, F. Anti-TIGIT therapies for solid tumors: A systematic review. ESMO Open 8, 101184 (2023).","journal-title":"ESMO Open"},{"key":"67263_CR24","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00262-025-04128-7","volume":"74","author":"EC Sundstrom","year":"2025","unstructured":"Sundstrom, E. C., Huang, X. & Wiemer, A. J. Anti-TIGIT therapies: A review of preclinical and clinical efficacy and mechanisms. Cancer Immunol. Immunother. CII 74, 272 (2025).","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"67263_CR25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/cmi.2011.52","volume":"9","author":"HJ Lee","year":"2012","unstructured":"Lee, H. J. et al. Identification of novel HLA-A*0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancer. Cell. Mol. Immunol. 9, 175\u2013183 (2012).","journal-title":"Cell. Mol. Immunol."},{"key":"67263_CR26","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1182\/blood-2007-03-082529","volume":"110","author":"J Qian","year":"2007","unstructured":"Qian, J. et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 110, 1587\u20131594 (2007).","journal-title":"Blood"},{"key":"67263_CR27","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1158\/1078-0432.CCR-03-0640","volume":"10","author":"K Schag","year":"2004","unstructured":"Schag, K. et al. Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes. Clin Cancer Res. 10, 3658\u20133666 (2004).","journal-title":"Clin Cancer Res"},{"key":"67263_CR28","doi-asserted-by":"publisher","first-page":"31448","DOI":"10.18632\/oncotarget.25837","volume":"9","author":"M Tsukagoshi","year":"2018","unstructured":"Tsukagoshi, M. et al. Identification of a novel HLA-A24-restricted cytotoxic T lymphocyte epitope peptide derived from mesothelin in pancreatic cancer. Oncotarget 9, 31448\u201331458 (2018).","journal-title":"Oncotarget"},{"key":"67263_CR29","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1097\/MPA.0b013e31821ad8d1","volume":"40","author":"S Yamazoe","year":"2011","unstructured":"Yamazoe, S. et al. Identification of HLA-A*0201- and A*2402-restricted epitopes of mucin 5AC expressed in advanced pancreatic cancer. Pancreas 40, 896\u2013904 (2011).","journal-title":"Pancreas"},{"key":"67263_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-02222-w","volume":"22","author":"J Yang","year":"2021","unstructured":"Yang, J. et al. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic ductal adenocarcinoma. Genome Biol. 22, 4 (2021).","journal-title":"Genome Biol."},{"key":"67263_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020).","journal-title":"Science"},{"key":"67263_CR32","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa, R. et al. Base-Edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N. Engl. J. Med. 389, 899\u2013910 (2023).","journal-title":"N. Engl. J. Med."},{"key":"67263_CR33","doi-asserted-by":"publisher","first-page":"1315283","DOI":"10.3389\/fimmu.2024.1315283","volume":"15","author":"BC Cianciotti","year":"2024","unstructured":"Cianciotti, B. C. et al. TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells. Front. Immunol. 15, 1315283 (2024).","journal-title":"Front. Immunol."},{"key":"67263_CR34","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41587-023-01915-4","volume":"42","author":"M Fiumara","year":"2024","unstructured":"Fiumara, M. et al. Genotoxic effects of base and prime editing in human hematopoietic stem cells. Nat. Biotechnol. 42, 877\u2013891 (2024).","journal-title":"Nat. Biotechnol."},{"key":"67263_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13007-6","volume":"10","author":"BR Webber","year":"2019","unstructured":"Webber, B. R. et al. Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nat. Commun. 10, 5222 (2019).","journal-title":"Nat. Commun."},{"key":"67263_CR36","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","volume":"604","author":"RC Larson","year":"2022","unstructured":"Larson, R. C. et al. CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours. Nature 604, 563\u2013570 (2022).","journal-title":"Nature"},{"key":"67263_CR37","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","volume":"40","author":"MB Leick","year":"2022","unstructured":"Leick, M. B. et al. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell 40, 494\u2013508.e5 (2022).","journal-title":"Cancer Cell"},{"key":"67263_CR38","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","volume":"23","author":"G Oliveira","year":"2023","unstructured":"Oliveira, G. & Wu, C. J. Dynamics and specificities of T cells in cancer immunotherapy. Nat. Rev. Cancer 23, 295\u2013316 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"67263_CR39","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1515\/hsz-2023-0341","volume":"405","author":"A Carr","year":"2024","unstructured":"Carr, A. et al. Advances in preclinical TCR characterization: leveraging cell avidity to identify functional TCRs. Biol. Chem. 405, 517\u2013529 (2024).","journal-title":"Biol. Chem."},{"key":"67263_CR40","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219\u20131226 (2018).","journal-title":"Cancer Discov."},{"key":"67263_CR41","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner, R. et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127, 2406\u20132410 (2016).","journal-title":"Blood"},{"key":"67263_CR42","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Vi\u00e0","year":"2021","unstructured":"Da Vi\u00e0, M. C. et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat. Med. 27, 616\u2013619 (2021).","journal-title":"Nat. Med."},{"key":"67263_CR43","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi, B. D. et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N. Engl. J. Med. 390, 1290\u20131298 (2024).","journal-title":"N. Engl. J. Med."},{"key":"67263_CR44","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","volume":"596","author":"G Oliveira","year":"2021","unstructured":"Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature 596, 119\u2013125 (2021).","journal-title":"Nature"},{"key":"67263_CR45","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","volume":"55","author":"KL Banta","year":"2022","unstructured":"Banta, K. L. et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses. Immunity 55, 512\u2013526.e9 (2022).","journal-title":"Immunity"},{"key":"67263_CR46","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0952-7915(99)80040-5","volume":"11","author":"JE van Leeuwen","year":"1999","unstructured":"van Leeuwen, J. E. & Samelson, L. E. T cell antigen-receptor signal transduction. Curr. Opin. Immunol. 11, 242\u2013248 (1999).","journal-title":"Curr. Opin. Immunol."},{"key":"67263_CR47","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S1074-7613(01)00244-8","volume":"15","author":"F Michel","year":"2001","unstructured":"Michel, F., Attal-Bonnefoy, G., Mangino, G., Mise-Omata, S. & Acuto, O. CD28 as a molecular amplifier extending TCR ligation and signaling capabilities. Immunity 15, 935\u2013945 (2001).","journal-title":"Immunity"},{"key":"67263_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00451-w","volume":"6","author":"K Shah","year":"2021","unstructured":"Shah, K., Al-Haidari, A., Sun, J. & Kazi, J. U. T cell receptor (TCR) signaling in health and disease. Signal Transduct. Target. Ther. 6, 1\u201326 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"67263_CR49","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S1074-7613(01)00112-1","volume":"14","author":"SC Bunnell","year":"2001","unstructured":"Bunnell, S. C., Kapoor, V., Trible, R. P., Zhang, W. & Samelson, L. E. Dynamic actin polymerization drives T cell receptor-induced spreading: a role for the signal transduction adaptor LAT. Immunity 14, 315\u2013329 (2001).","journal-title":"Immunity"},{"key":"67263_CR50","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.aad9964","volume":"352","author":"X Su","year":"2016","unstructured":"Su, X. et al. Phase separation of signaling molecules promotes T cell receptor signal transduction. Science 352, 595\u2013599 (2016).","journal-title":"Science"},{"key":"67263_CR51","doi-asserted-by":"publisher","unstructured":"Wabnitz, G., Kirchgessner, H. & Samstag, Y. Qualitative and quantitative analysis of the immune synapse in the human system using imaging flow cytometry. J. Vis. Exp. JoVE https:\/\/doi.org\/10.3791\/55345 (2019).","DOI":"10.3791\/55345"},{"key":"67263_CR52","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1074-7613(00)70060-4","volume":"4","author":"A Shibuya","year":"1996","unstructured":"Shibuya, A. et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 4, 573\u2013581 (1996).","journal-title":"Immunity"},{"key":"67263_CR53","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1074-7613(00)80136-3","volume":"11","author":"K Shibuya","year":"1999","unstructured":"Shibuya, K. et al. Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. Immunity 11, 615\u2013623 (1999).","journal-title":"Immunity"},{"key":"67263_CR54","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1084\/jem.20030958","volume":"198","author":"K Shibuya","year":"2003","unstructured":"Shibuya, K. et al. CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. J. Exp. Med. 198, 1829\u20131839 (2003).","journal-title":"J. Exp. Med."},{"key":"67263_CR55","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1084\/jem.20081752","volume":"205","author":"S Gilfillan","year":"2008","unstructured":"Gilfillan, S. et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J. Exp. Med. 205, 2965\u20132973 (2008).","journal-title":"J. Exp. Med."},{"key":"67263_CR56","first-page":"1338","volume":"186","author":"N Joller","year":"2011","unstructured":"Joller, N. et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J. Immunol. Baltim. Md 1950 186, 1338\u20131342 (2011).","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"67263_CR57","first-page":"553","volume":"192","author":"KM Ramsbottom","year":"2014","unstructured":"Ramsbottom, K. M. et al. Cutting edge: DNAX accessory molecule 1-deficient CD8+ T cells display immunological synapse defects that impair antitumor immunity. J. Immunol. Baltim. Md 1950 192, 553\u2013557 (2014).","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"67263_CR58","doi-asserted-by":"publisher","first-page":"688961","DOI":"10.3389\/fimmu.2021.688961","volume":"12","author":"Q Shao","year":"2021","unstructured":"Shao, Q. et al. TIGIT Induces (CD3+) T cell dysfunction in colorectal cancer by inhibiting glucose metabolism. Front. Immunol. 12, 688961 (2021).","journal-title":"Front. Immunol."},{"key":"67263_CR59","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12964-023-01455-z","volume":"22","author":"M Huang","year":"2024","unstructured":"Huang, M. et al. The immune checkpoint TIGIT\/CD155 promotes the exhaustion of CD8\u2009+\u2009T cells in TNBC through glucose metabolic reprogramming mediated by PI3K\/AKT\/mTOR signaling. Cell Commun. Signal. CCS 22, 35 (2024).","journal-title":"Cell Commun. Signal. CCS"},{"key":"67263_CR60","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nbt.3816","volume":"35","author":"K Kim","year":"2017","unstructured":"Kim, K. et al. Highly efficient RNA-guided base editing in mouse embryos. Nat. Biotechnol. 35, 435\u2013437 (2017).","journal-title":"Nat. Biotechnol."},{"key":"67263_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15790","volume":"8","author":"HA Rees","year":"2017","unstructured":"Rees, H. A. et al. Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery. Nat. Commun. 8, 15790 (2017).","journal-title":"Nat. Commun."},{"key":"67263_CR62","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/eji.202049103","volume":"51","author":"F Manfredi","year":"2021","unstructured":"Manfredi, F. et al. Flow cytometry data mining by cytoChain identifies determinants of exhaustion and stemness in TCR-engineered T cells. Eur. J. Immunol. 51, 1992\u20132005 (2021).","journal-title":"Eur. J. Immunol."},{"key":"67263_CR63","doi-asserted-by":"publisher","first-page":"S581","DOI":"10.1016\/j.jtct.2024.11.017","volume":"31","author":"AN Shoushtari","year":"2025","unstructured":"Shoushtari, A. N. & Powell, D. J. Tumor-infiltrating lymphocyte therapy for melanoma and other solid tumors: Looking back, yet moving forward. Transplant. Cell. Ther. 31, S581\u2013S590 (2025).","journal-title":"Transplant. Cell. Ther."},{"key":"67263_CR64","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"67263_CR65","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong, D. S. et al. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: A phase 1 trial. Nat. Med. 29, 104\u2013114 (2023).","journal-title":"Nat. Med."},{"key":"67263_CR66","unstructured":"Commissioner, O. of the. FDA Approves First Gene Therapy to Treat Adults with Metastatic Synovial Sarcoma. FDA https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treat-adults-metastatic-synovial-sarcoma (2024)."},{"key":"67263_CR67","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong, M., Clubb, J. D. & Chen, Y. Y. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell 38, 473\u2013488 (2020).","journal-title":"Cancer Cell"},{"key":"67263_CR68","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1089\/hum.2023.128","volume":"34","author":"C Bonini","year":"2023","unstructured":"Bonini, C. et al. Genome editing in engineered T cells for cancer immunotherapy. Hum. Gene Ther. 34, 853\u2013869 (2023).","journal-title":"Hum. Gene Ther."},{"key":"67263_CR69","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00281-024-01011-y","volume":"46","author":"M Spiga","year":"2024","unstructured":"Spiga, M. et al. Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors. Semin. Immunopathol. 46, 8 (2024).","journal-title":"Semin. Immunopathol."},{"key":"67263_CR70","first-page":"5039","volume":"186","author":"E Corse","year":"2011","unstructured":"Corse, E., Gottschalk, R. A. & Allison, J. P. Strength of TCR-peptide\/MHC interactions and in vivo T cell responses. J. Immunol. Baltim. Md 1950 186, 5039\u20135045 (2011).","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"67263_CR71","doi-asserted-by":"publisher","first-page":"e007502","DOI":"10.1136\/jitc-2023-007502","volume":"11","author":"MF Hasan","year":"2023","unstructured":"Hasan, M. F. et al. Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies. J. Immunother. Cancer 11, e007502 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"67263_CR72","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella, M. et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat. Med. 24, 1499\u20131503 (2018).","journal-title":"Nat. Med."},{"key":"67263_CR73","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine, B. L. et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat. Med. 30, 338\u2013341 (2024).","journal-title":"Nat. Med."},{"key":"67263_CR74","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","volume":"390","author":"M Ozdemirli","year":"2024","unstructured":"Ozdemirli, M. et al. Indolent CD4+ CAR T-cell lymphoma after cilta-cel CAR T-cell therapy. N. Engl. J. Med. 390, 2074\u20132082 (2024).","journal-title":"N. Engl. J. Med."},{"key":"67263_CR75","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","volume":"38","author":"AV Anzalone","year":"2020","unstructured":"Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 38, 824\u2013844 (2020).","journal-title":"Nat. Biotechnol."},{"key":"67263_CR76","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.stem.2019.02.019","volume":"24","author":"G Schiroli","year":"2019","unstructured":"Schiroli, G. et al. Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response. Cell Stem Cell 24, 551\u2013565.e8 (2019).","journal-title":"Cell Stem Cell"},{"key":"67263_CR77","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","volume":"53","author":"ML Leibowitz","year":"2021","unstructured":"Leibowitz, M. L. et al. Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing. Nat. Genet. 53, 895\u2013905 (2021).","journal-title":"Nat. Genet."},{"key":"67263_CR78","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.stem.2021.02.002","volume":"28","author":"G Turchiano","year":"2021","unstructured":"Turchiano, G. et al. Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq. Cell Stem Cell 28, 1136\u20131147.e5 (2021).","journal-title":"Cell Stem Cell"},{"key":"67263_CR79","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1016\/j.cell.2023.08.041","volume":"186","author":"CA Tsuchida","year":"2023","unstructured":"Tsuchida, C. A. et al. Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. Cell 186, 4567\u20134582.e20 (2023).","journal-title":"Cell"},{"key":"67263_CR80","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.omtm.2020.09.002","volume":"19","author":"R Preece","year":"2020","unstructured":"Preece, R. et al. CRISPR-mediated base conversion allows discriminatory depletion of endogenous T cell receptors for enhanced synthetic immunity. Mol. Ther. Methods Clin. Dev. 19, 149\u2013161 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"67263_CR81","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1038\/s41375-021-01282-6","volume":"35","author":"C Georgiadis","year":"2021","unstructured":"Georgiadis, C. et al. Base-edited CAR T cells for combinational therapy against T cell malignancies. Leukemia 35, 3466\u20133481 (2021).","journal-title":"Leukemia"},{"key":"67263_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15887-5","volume":"11","author":"Y Yu","year":"2020","unstructured":"Yu, Y. et al. Cytosine base editors with minimized unguided DNA and RNA off-target events and high on-target activity. Nat. Commun. 11, 2052 (2020).","journal-title":"Nat. Commun."},{"key":"67263_CR83","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41587-020-0414-6","volume":"38","author":"JL Doman","year":"2020","unstructured":"Doman, J. L., Raguram, A., Newby, G. A. & Liu, D. R. Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors. Nat. Biotechnol. 38, 620\u2013628 (2020).","journal-title":"Nat. Biotechnol."},{"key":"67263_CR84","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli, N. M. et al. Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage. Nature 551, 464\u2013471 (2017).","journal-title":"Nature"},{"key":"67263_CR85","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00109-005-0680-2","volume":"83","author":"M Buchholz","year":"2005","unstructured":"Buchholz, M. et al. Transcriptome analysis of human hepatic and pancreatic stellate cells: organ-specific variations of a common transcriptional phenotype. J. Mol. Med. Berl. Ger. 83, 795\u2013805 (2005).","journal-title":"J. Mol. Med. Berl. Ger."},{"key":"67263_CR86","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1371\/journal.pone.0000323","volume":"2","author":"AW Lowe","year":"2007","unstructured":"Lowe, A. W. et al. Gene expression patterns in pancreatic tumors, cells and tissues. PLOS ONE 2, e323 (2007).","journal-title":"PLOS ONE"},{"key":"67263_CR87","first-page":"2016","volume":"55","author":"L Badea","year":"2008","unstructured":"Badea, L., Herlea, V., Dima, S. O., Dumitrascu, T. & Popescu, I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology 55, 2016\u20132027 (2008).","journal-title":"Hepatogastroenterology"},{"key":"67263_CR88","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500\u2013503 (2011).","journal-title":"Nat. Med."},{"key":"67263_CR89","doi-asserted-by":"publisher","first-page":"e93046","DOI":"10.1371\/journal.pone.0093046","volume":"9","author":"NCW Goonesekere","year":"2014","unstructured":"Goonesekere, N. C. W., Wang, X., Ludwig, L. & Guda, C. A meta analysis of pancreatic microarray datasets yields new targets as cancer genes and biomarkers. PLOS ONE 9, e93046 (2014).","journal-title":"PLOS ONE"},{"key":"67263_CR90","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168\u20131178 (2015).","journal-title":"Nat. Genet."},{"key":"67263_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0358-5","volume":"14","author":"S M\u00fcller","year":"2015","unstructured":"M\u00fcller, S. et al. Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer. Mol. Cancer 14, 94 (2015).","journal-title":"Mol. Cancer"},{"key":"67263_CR92","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47\u201352 (2016).","journal-title":"Nature"},{"key":"67263_CR93","doi-asserted-by":"publisher","first-page":"42537","DOI":"10.18632\/oncotarget.16451","volume":"8","author":"Y Mao","year":"2017","unstructured":"Mao, Y. et al. RNA sequencing analyses reveal novel differentially expressed genes and pathways in pancreatic cancer. Oncotarget 8, 42537\u201342547 (2017).","journal-title":"Oncotarget"},{"key":"67263_CR94","doi-asserted-by":"crossref","unstructured":"Klett, H. et al. Identification and validation of a diagnostic and prognostic multi-gene biomarker panel for pancreatic ductal adenocarcinoma. Front. Genet. 9, 108 (2018).","DOI":"10.3389\/fgene.2018.00108"},{"key":"67263_CR95","first-page":"2453","volume":"16","author":"Y Tang","year":"2018","unstructured":"Tang, Y., Zhang, Z., Tang, Y., Chen, X. & Zhou, J. Identification of potential target genes in pancreatic ductal adenocarcinoma by bioinformatics analysis. Oncol. Lett. 16, 2453\u20132461 (2018).","journal-title":"Oncol. Lett."},{"key":"67263_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4546-8","volume":"18","author":"L Zhao","year":"2018","unstructured":"Zhao, L., Zhao, H. & Yan, H. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes. BMC Cancer 18, 603 (2018).","journal-title":"BMC Cancer"},{"key":"67263_CR97","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1136\/gutjnl-2018-317706","volume":"68","author":"C Maurer","year":"2019","unstructured":"Maurer, C. et al. Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes. Gut 68, 1034\u20131043 (2019).","journal-title":"Gut"},{"key":"67263_CR98","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41422-019-0195-y","volume":"29","author":"J Peng","year":"2019","unstructured":"Peng, J. et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res. 29, 725\u2013738 (2019).","journal-title":"Cell Res."},{"key":"67263_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00776-9","volume":"12","author":"W Lin","year":"2020","unstructured":"Lin, W. et al. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Genome Med 12, 80 (2020).","journal-title":"Genome Med"},{"key":"67263_CR100","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.3389\/fimmu.2019.01832","volume":"10","author":"M Bassani-Sternberg","year":"2019","unstructured":"Bassani-Sternberg, M. et al. A phase Ib study of the combination of personalized autologous dendritic cell vaccine, aspirin, and standard of care adjuvant chemotherapy followed by nivolumab for resected pancreatic adenocarcinoma-A proof of antigen discovery feasibility in three patients. Front. Immunol. 10, 1832 (2019).","journal-title":"Front. Immunol."},{"key":"67263_CR101","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1016\/j.molimm.2009.06.021","volume":"46","author":"K Antwi","year":"2009","unstructured":"Antwi, K. et al. Proteomic identification of an MHC-binding peptidome from pancreas and breast cancer cell lines. Mol. Immunol. 46, 2931\u20132937 (2009).","journal-title":"Mol. Immunol."},{"key":"67263_CR102","doi-asserted-by":"publisher","first-page":"e0190638","DOI":"10.1371\/journal.pone.0190638","volume":"13","author":"YJ Choi","year":"2018","unstructured":"Choi, Y. J. et al. EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells. PLOS ONE 13, e0190638 (2018).","journal-title":"PLOS ONE"},{"key":"67263_CR103","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2015.09.022","volume":"28","author":"IM Stromnes","year":"2015","unstructured":"Stromnes, I. M. et al. T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell 28, 638\u2013652 (2015).","journal-title":"Cancer Cell"},{"key":"67263_CR104","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1158\/1078-0432.CCR-05-0596","volume":"11","author":"J Yokokawa","year":"2005","unstructured":"Yokokawa, J. et al. Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 11, 6342\u20136351 (2005).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"67263_CR105","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.3892\/ijo.2013.1834","volume":"42","author":"Z-L Duan","year":"2013","unstructured":"Duan, Z.-L. et al. Two novel squamous cell carcinoma antigen-derived HLA-A*0201-binding peptides induce in vitro and in vivo CD8+ cytotoxic T lymphocyte responses. Int. J. Oncol. 42, 1482\u20131492 (2013).","journal-title":"Int. J. Oncol."},{"key":"67263_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-156","volume":"10","author":"NL Berinstein","year":"2012","unstructured":"Berinstein, N. L. et al. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J. Transl. Med. 10, 156 (2012).","journal-title":"J. Transl. Med."},{"key":"67263_CR107","unstructured":"Poon, E. C. C. Assessment of TWIST1 as an immunotherapeutic target of cancer. Doctoral dissertation. Institute of Child Health, University College London, (2011)."},{"key":"67263_CR108","first-page":"1037","volume":"163","author":"Y Rongcun","year":"1999","unstructured":"Rongcun, Y. et al. Identification of new HER2\/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J. Immunol. Baltim. Md 1950 163, 1037\u20131044 (1999).","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"67263_CR109","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1002\/1521-4141(200111)31:11<3261::AID-IMMU3261>3.0.CO;2-4","volume":"31","author":"A Scardino","year":"2001","unstructured":"Scardino, A. et al. Identification of HER-2\/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur. J. Immunol. 31, 3261\u20133270 (2001).","journal-title":"Eur. J. Immunol."},{"key":"67263_CR110","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1002\/1521-4141(200011)30:11<3338::AID-IMMU3338>3.0.CO;2-3","volume":"30","author":"T Okugawa","year":"2000","unstructured":"Okugawa, T. et al. A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals. Eur. J. Immunol. 30, 3338\u20133346 (2000).","journal-title":"Eur. J. Immunol."},{"key":"67263_CR111","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1158\/1078-0432.CCR-05-1672","volume":"12","author":"B Kubuschok","year":"2006","unstructured":"Kubuschok, B. et al. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 12, 1365\u20131372 (2006).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"67263_CR112","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1002\/1521-4141(2000)30:8<2216::AID-IMMU2216>3.0.CO;2-7","volume":"30","author":"M Schirle","year":"2000","unstructured":"Schirle, M. et al. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur. J. Immunol. 30, 2216\u20132225 (2000).","journal-title":"Eur. J. Immunol."},{"key":"67263_CR113","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.aad1253","volume":"350","author":"E Tran","year":"2015","unstructured":"Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387\u20131390 (2015).","journal-title":"Science"},{"key":"67263_CR114","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1002\/eji.201242517","volume":"42","author":"DA Bolotin","year":"2012","unstructured":"Bolotin, D. A. et al. Next generation sequencing for TCR repertoire profiling: platform-specific features and correction algorithms. Eur. J. Immunol. 42, 3073\u20133083 (2012).","journal-title":"Eur. J. Immunol."},{"key":"67263_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9081","volume":"6","author":"E Ruggiero","year":"2015","unstructured":"Ruggiero, E. et al. High-resolution analysis of the human T-cell receptor repertoire. Nat. Commun. 6, 8081 (2015).","journal-title":"Nat. Commun."},{"key":"67263_CR116","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1200\/JCO.24.00410","volume":"43","author":"SJ Klempner","year":"2025","unstructured":"Klempner, S. J. et al. DKN-01 in combination with tislelizumab and chemotherapy as first-line therapy in advanced gastric or gastroesophageal junction adenocarcinoma: DisTinGuish. J. Clin. Oncol. 43, 339\u2013349 (2025).","journal-title":"J. Clin. Oncol."},{"key":"67263_CR117","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1089\/crispr.2018.0014","volume":"1","author":"MG Kluesner","year":"2018","unstructured":"Kluesner, M. G. et al. EditR: A method to quantify base editing from Sanger sequencing. CRISPR J. 1, 239\u2013250 (2018).","journal-title":"CRISPR J."},{"key":"67263_CR118","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nbt1049","volume":"23","author":"M Amendola","year":"2005","unstructured":"Amendola, M., Venneri, M. A., Biffi, A., Vigna, E. & Naldini, L. Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat. Biotechnol. 23, 108\u2013116 (2005).","journal-title":"Nat. Biotechnol."},{"key":"67263_CR119","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1038\/mt.2012.96","volume":"20","author":"C L\u00e9vy","year":"2012","unstructured":"L\u00e9vy, C. et al. Lentiviral vectors displaying modified measles virus gp overcome pre-existing immunity in in vivo-like transduction of human T and B cells. Mol. Ther. J. Am. Soc. Gene Ther. 20, 1699\u20131712 (2012).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"67263_CR120","doi-asserted-by":"publisher","first-page":"897047","DOI":"10.3389\/fimmu.2022.897047","volume":"13","author":"R Tang","year":"2022","unstructured":"Tang, R. et al. Enhanced T cell glucose uptake is associated with progression of beta-cell function in type 1 diabetes. Front. Immunol. 13, 897047 (2022).","journal-title":"Front. Immunol."},{"key":"67263_CR121","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis, G. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359, 920 (2018).","journal-title":"Science"},{"key":"67263_CR122","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1038\/s41596-020-0379-4","volume":"15","author":"E Driehuis","year":"2020","unstructured":"Driehuis, E., Kretzschmar, K. & Clevers, H. Establishment of patient-derived cancer organoids for drug-screening applications. Nat. Protoc. 15, 3380\u20133409 (2020).","journal-title":"Nat. Protoc."},{"key":"67263_CR123","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41596-019-0232-9","volume":"15","author":"CM Cattaneo","year":"2020","unstructured":"Cattaneo, C. M. et al. Tumor organoid-T-cell coculture systems. Nat. Protoc. 15, 15\u201339 (2020).","journal-title":"Nat. Protoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67263-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67263-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67263-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T15:04:40Z","timestamp":1768489480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67263-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":123,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67263"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67263-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CBo has been member of Advisory Board and Consultant for Intellia, TxCell, Novartis, GSK, Allogene, Kite\/Gilead, Kiadis, Evir, Janssen, Genyo, Epsilen, and received research support from Intellia Therapeutics. MS, AP, ER, and CBo are inventors in the patent WO2025\/003481 including TCRs and sgRNAs employed in this work. AP, ZM, ER, CBo are inventors on different patents on cancer immunotherapy and genetic engineering. L.N. is founder of, quota holder and consultant for GeneSpire and Epsilen Bio\/Chroma Medicine. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"568"}}